Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Epilepsy is one of the most common neurological diseases in Italy, affecting about 500,000 people. Pediatric age represents one of the most affected groups with a consequent significant impact on the quality of life of the families involved.
The study aims to monitor the cognitive functions of patients followed at our center in order to determine the main types of pathways and highlight their determinants. The ultimate goal is to define what are the main clinical and instrumental predictors of cognitive function and its variation over time.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| neurodevelopment level | Evaluate prescholar global development and scholar cognitive level with Griffiths or Weschler scales where applicable according to age. | 12 months after entry visit |
| Measure | Description | Time Frame |
|---|---|---|
| Seizure outcome | Evaluate the reduction in seizures (percentage) | 24 months after entry visit |
| QOLIE-31 | Evaluate the Impact of the Epilepsy on the quality of life |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
People with epilepsy seen at the Children's Neuropsychiatry of the Fondazione Policlinico Gemelli IRCCS (UOS Diagnosis and Treatment of Drug-Resistant Epilepsies, Day Hospital or inpatient setting at the Department of Children's Neuropsychiatry). Epilepsy is defined according to 2014 ILAE criteria: (1) at least two unprovoked (or reflex) seizures occurring more than 24 h apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years; (3) diagnosis of an epilepsy syndrome.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Domenica Immacolata Battaglia, MD | Contact | +39 0630159222 | domenicaimmacolata.battaglia@policlinicogemelli.it | |
| Michela Quintiliani, MD | Contact | +39 0630159222 | michela.quintiliani@guest.policlinicogemelli.it |
| Name | Affiliation | Role |
|---|---|---|
| Domenica Immacolata Battaglia | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | Rome | 00168 | Italy |
Not provided
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 24 months after entry visit |
| Clinical Global Impression Scale | Evaluate the global clinical impression to have a measure of epilepsy severity and the burden of antiseizure medication on daily life. | 24 months after entry visit |